Natural Autoantibodies Cross-React with a Peptide Derived from the Second Conserved Region of HIV-1 Envelope Glycoprotein gp120

Veljković, Veljko; Metlas, Radmila; Danilo, Villalta; Cavor, L.; Pejinovic, N.; Dujuc, A.; Zakhariev, S.; Guarnaccia, Corrado; Pongor, Sándor

doi:10.1006/bbrc.1993.2353

Cited by 19 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously we showed that VIP and NTM, despite significantly different primary structures, have very similar IS (13). It has been also shown that NTM and VIP are immunologically crossreactive (14). For this reason VIP was used as a natural mimetic of NTM.…”

Section: Resultsmentioning

confidence: 99%

Design of peptide mimetics of HIV‐1 gp120 for prevention and therapy of HIV disease

Veljković¹,

Branch²,

Metlaš³

et al. 2003

The Journal of Peptide Research

Self Cite

View full text Add to dashboard Cite

It has been reported that the C-terminus of the second conserved region (C2) of the envelope glycoprotein gp120, encompassing peptide RSANFTDNAKTIIVQLNESVEIN (NTM), is important for infectivity and neutralization of the human immunodeficiency virus type 1 (HIV-1). It was also demonstrated that human natural anti-vasoactive intestinal peptide (VIP) antibodies reactive with this gp120 region play an important role in control of HIV disease progression. The bioinformatic analysis based on the time-frequency signal processing revealed non-obvious similarities between NTM and VIP. When tested against a battery of sera from 46 AIDS patients, these peptides, in spite of a significant difference in their primary structures, showed a similar reactivity profiles (r = 0.83). Presented results point out that similarity in the periodical pattern of some physicochemical properties in primary structures of peptides plays a significant role in determination of their immunological crossreactivity. Based on these findings, we propose this bioinformatic criterion be used for design of VIP/NTM peptide mimetics for prevention and treatment of HIV disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Design of peptide mimetics of HIV‐1 gp120 for prevention and therapy of HIV disease

Veljković¹,

Branch²,

Metlaš³

et al. 2003

The Journal of Peptide Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…VIP antibodies cross reactive with gp120 (Velikovic et al, 1993) A potent anti-inflammatory peptide that induces regulatory T cells (Anderson & Gonzalez-Rey, 2010). Also regulates dendritic cell differentiation and Toll receptor signalling (Chorny et al, 2006;Arranz et al, 2008) Miscellaneous DDX17 NP_001091974.1| DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 P72: cross-reacts with the murine leukaemia virus p15-gag antigen (Rucheton et al, 1992) Regulates oestrogen receptor alpha transcription (Wortham et al, 2009).…”

Section: Methodsmentioning

confidence: 99%

Extensive viral mimicry of 22 AIDS-related autoantigens by HIV-1 proteins and pathway analysis of 561 viral/human homologues suggest an initial treatable autoimmune component of AIDS

Carter

2011

FEMS Immunol Med Microbiol

View full text Add to dashboard Cite

HIV-1 viral proteins, particularly the env protein, are homologous to 22 AIDS autoantigens, suggesting their creation by antiviral antibodies subsequently targeting human homologues. They include antibodies to T-cell receptors, CD4 and CD95, complement components, IgG, TNF and other immune-related proteins. Autoantibodies may compromise the immune system via knockdown of these key proteins, and autoimmune attack on the immune system itself, as supported by immune activation in early stages of infection and during the transition to AIDS. Over 500 human proteins contain pentapeptides or longer consensi, identical to viral peptides. Such homology explains the extensive viral/human interactome, likely related to the ability of viral homologues to compete with human counterparts as binding partners. Pathway analysis of these homologous proteins revealed their involvement in immune-related networks (e.g. natural killer cell toxicity/toll, T-cell/B-cell receptor signalling/antigen processing) and viral and bacterial entry and defence pathways (phagosome/lysosome pathways, DNA sensing/NOD/RIG-1 pathways) relevant to AIDS pathogenesis. At its inception, AIDS may have an autoimmune component selectively targeting the immune system. Immunosuppressive therapy or antibody removal, which has already achieved some success, might be therapeutically beneficial, particularly if targeted at removal of the culpable antibodies, via affinity dialysis.

show abstract

“…It has been proposed that these antibodies represent natural anti-vasoactive intestinal peptide (VIP) antibodies, because the domain of the HIV-1 gp120 encompassing peptide C2 is not immunogenic in humans (Veljković et al, 1992(Veljković et al, , 1993. Recently we demonstrated that peptide RSANFTDNAKTI-IVQLNESVEIN derived from peptide C2 and VIP showed similar reactivity profiles when tested against a battery of sera from 46 AIDS patients (Veljkovic et al, 2003).…”

Section: Resultsmentioning

confidence: 88%

“…It has been demonstrated that antibodies with specific affinity (or cross reactivity) to the HIV-1 envelope protein (gp120 surface antigen, residues 280-302, RSANFTDNAK-TIIVQLNQSVEIN, designated peptide NTM), which represent, in fact, naturally occurring autoantibodies (designated as anti-VIP/NTM antibodies) with a specificity to vasoactive intestinal peptide (VIP) (Veljković et al, 1992(Veljković et al, , 1993, may be directly involved in control of HIV disease progression (Neurath et al, 1990;Veljković et al, 2001b;Branch et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease

Veljković

Branch

Metlas³

et al. 2004

Journal of Clinical Virology

View full text Add to dashboard Cite

Natural Autoantibodies Cross-React with a Peptide Derived from the Second Conserved Region of HIV-1 Envelope Glycoprotein gp120

Cited by 19 publications

References 0 publications

Design of peptide mimetics of HIV‐1 gp120 for prevention and therapy of HIV disease

Design of peptide mimetics of HIV‐1 gp120 for prevention and therapy of HIV disease

Extensive viral mimicry of 22 AIDS-related autoantigens by HIV-1 proteins and pathway analysis of 561 viral/human homologues suggest an initial treatable autoimmune component of AIDS

Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease

Contact Info

Product

Resources

About